v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | EUCTR2021-002476-39-IT |
Full text link
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002476-39/IT |
First author
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
|
Contact
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Flavio.Mantelli@dompe.com |
Registration date
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
2021-08-30 |
Recruitment status
Last imported at : March 13, 2022, 2:55 p.m. Source : EU Clinical Trials Register |
Terminated |
Study design
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
nonRCT |
Allocation
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Non-randomized |
Design
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Parallel |
Masking
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Open label |
Center
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
multi-center |
Study aim
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Prevention |
Inclusion criteria
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Females Age > 50 years old Patients who are under Raloxifene therapy as a prevention strategy or treatment of osteoporosis OR Subjects who are taking alendronate as a prevention strategy for osteoporosis OR Subjects who are taking Vit. D and Calcium as a prevention approach for osteoporosis OR Subjects who are not receiving any osteoporosis preventive treatment or treatment AND Who have received the first dose of a COVID vaccination, or who have received the full vaccination within 8 weeks prior to the first planned blood collection. All approved COVID vaccines are accepted. Donne di età> 50 anni Pazienti sottoposti a terapia con Raloxifene come strategia di prevenzione o trattamento dell'osteoporosi O Soggetti che assumono alendronato come strategia di prevenzione per l'osteoporosi O Soggetti che assumono Vit. D e Calcio come approccio di prevenzione per l'osteoporosi O Soggetti che non ricevono alcun trattamento come strategia di prevenzione o trattamento per l'osteoporosi E che hanno ricevuto la prima dose di una vaccinazione COVID o che hanno ricevuto la vaccinazione completa entro 8 settimane prima del primo prelievo di sangue pianificato. Tutti i vaccini COVID approvati sono accettati. |
Exclusion criteria
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Subjects who are SARS-CoV-2 positive Subjects who have received the complete COVID vaccination more than 8 weeks prior to the first planned blood collection Immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection, asplenia, and recurrent severe infections Subjects who have received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the first planned blood collection (for corticosteroids =20 milligrams (mg)/day of prednisone equivalent) Subjects who have received systemic immunoglobulins or blood products within 3 months prior to the first planned blood collection Subjects who have received chemotherapy, radiation therapy or have undergone surgical intervention for cancer in the last 5 years Soggetti che sono SARS-CoV-2 positivi Soggetti che hanno ricevuto la vaccinazione COVID completa più di 8 settimane prima del primo prelievo di sangue pianificato Stato immunosoppressivo o immunodeficiente, inclusa l'infezione da virus dell'immunodeficienza umana (HIV), asplenia e infezioni gravi ricorrenti Soggetti che hanno ricevuto immunosoppressori sistemici o farmaci immunomodificanti per > 14 giorni in totale entro 6 mesi prima del primo prelievo di sangue pianificato (per corticosteroidi =20 milligrammi (mg) / giorno di prednisone equivalente) Soggetti che hanno ricevuto immunoglobuline sistemiche o emoderivati entro 3 mesi prima del primo prelievo di sangue pianificato Soggetti che hanno ricevuto chemioterapia, radioterapia o hanno subito un intervento chirurgico per cancro negli ultimi 5 anni. |
Number of arms
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
1 |
Funding
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
DOMPé FARMACEUTICI S.P.A. |
Inclusion age min
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
51 |
Inclusion age max
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
100 |
Countries
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Italy |
Type of patients
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Healthy volunteers |
Severity scale
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
N/A |
Total sample size
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
40 |
primary outcome
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Quantification of SARS-CoV-2 Specific Neutralizing Antibody (nAb) and S protein-specific Binding Antibody (bAb) levels in patients’ blood serum and measurement of GMTs (geometric mean titers) and GMFRs (geometric mean fold rises) in SARS-CoV-2 Specific Neutralizing Antibody (nAb) and S protein-specific Binding Antibody (bAb) at the different timepoints Quantificazione dei livelli di anticorpi neutralizzanti specifico per SARS-CoV-2 (nAb) e anticorpi specifici legante la proteina S (bAb) nel siero del paziente e misurazione delle GMT (media geometrica dei titoli) e GMFR (aumento della piega media geometrica) nei diversi punti temporali. |
Notes
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Declared number of arm (4.0) differs from found arms (1.0) |
Phase
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
Phase 4 |
Arms
Last imported at : Sept. 30, 2021, 9:03 a.m. Source : EU Clinical Trials Register |
[{"arm_notes": "Previously vaccinated with one approved COVID vaccines", "treatment_id": 1058, "treatment_name": "Raloxifene", "treatment_type": "Hormones", "pharmacological_treatment": "Pharmacological treatment"}] |